3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
30
Burkitt Lymphoma
24
Multiple Myeloma
21
Lymphoma, Large B-Cell, Diffuse
21
Leukemia, Myeloid, Acute
18
Lymphoma, Non-Hodgkin
16
Myelodysplastic Syndromes
15
Lymphoma, B-Cell
14
Lymphoma
14
Lymphoma, Follicular
12
Recurrence
11
Ovarian Neoplasms
11
Hodgkin Disease
11
Triple Negative Breast Neoplasms
10
Neoplasms
9
Lymphoma, Mantle-Cell
9
Leukemia, Lymphocytic, Chronic, B-Cell
9
Breast Neoplasms
9
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Pancreatic Neoplasms
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Leukemia
8
Hematologic Neoplasms
8
Sarcoma
6
Osteosarcoma
6
Leukemia, Myelomonocytic, Chronic
6
Colorectal Neoplasms
6
Lymphoma, B-Cell, Marginal Zone
5
Leukemia, Biphenotypic, Acute
5
Graft vs Host Disease
5
Interventions
pembrolizumab
32
Cisplatin
23
Cetuximab
14
Carboplatin
13
Magnetic Resonance Spectroscopy
12
Specimen Handling
10
Radiotherapy, Intensity-Modulated
10
Paclitaxel
9
Nivolumab
9
Docetaxel
8
Platinum
7
1,2-diaminocyclohexaneplatinum II citrate
7
Radiotherapy
5
Biopsy
5
dostarlimab
4
atezolizumab
4
Immunoglobulin G
4
Fluorouracil
4
Disulfides
4
Bevacizumab
4
(225)Ac-DOTA-c(RGDyK)
4
cemiplimab
3
Taxes
3
Radiation
3
Fulvestrant
3
budigalimab
2
amivantamab
2
abemaciclib
2
Radiotherapy, Image-Guided
2
Pemetrexed
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
Cyclophosphamide
×
30 days
×
Clear all
NCT07617805
2026-06-01
DUAL-HN
Beijing Biotech
Phase 1/2
Recruiting
42 enrolled